Risk Factors for Breast Cancer-Related Lymphedema, Risk Reduction, and Myths about Precautionary Behaviors

[11] Sayegh HE(2014)Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial Lancet Oncol 15 1303-1078

[12] Asdourian MS(2016)Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection J Clin Oncol 34 1072-2835

[13] Swaroop MN(2017)Considerations for clinicians in the diagnosis, prevention, and treatment of breast cancer-related lymphedema, recommendations from an expert panel: part 2: preventive and therapeutic options Ann Surg Oncol 24 2827-5751

[14] McLaughlin SA(2021)American Society of Breast Surgeons’ practice patterns for patients at risk and affected by breast cancer-related lymphedema Ann Surg Oncol 28 5742-11

[15] Staley AC(2013)the diagnosis and treatment of peripheral lymphedema: 2013 consensus document of the International Society of Lymphology Lymphology 46 1-316

[16] Vicini F(2018)Fifteen-year results of the randomised EORTC trial 22922/10925 investigating internal mammary and medial supraclavicular (IM-MS) lymph node irradiation in stage I-III breast cancer J Clin Oncol 36 504-2589

[17] DiSipio T(2015)Regional nodal irradiation in early-stage breast cancer N Engl J Med 373 307-1459

[18] Rye S(2012)Nomograms for predicting the risk of arm lymphedema after axillary dissection in breast cancer Ann Surg Oncol 19 2580-1972

[19] Newman B(2008)Incidence and risk factors of breast cancer lymphoedema J Clin Nurs 17 1450-3286

[20] Giuliano AE(2009)The risk of developing arm lymphedema among breast cancer survivors: a meta-analysis of treatment factors Ann Surg Oncol 16 1959-571

[11] Sayegh HE(2014)Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial Lancet Oncol 15 1303-1078

[12] Asdourian MS(2016)Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection J Clin Oncol 34 1072-2835

[13] Swaroop MN(2017)Considerations for clinicians in the diagnosis, prevention, and treatment of breast cancer-related lymphedema, recommendations from an expert panel: part 2: preventive and therapeutic options Ann Surg Oncol 24 2827-5751

[14] McLaughlin SA(2021)American Society of Breast Surgeons’ practice patterns for patients at risk and affected by breast cancer-related lymphedema Ann Surg Oncol 28 5742-11

[15] Staley AC(2013)the diagnosis and treatment of peripheral lymphedema: 2013 consensus document of the International Society of Lymphology Lymphology 46 1-316

[16] Vicini F(2018)Fifteen-year results of the randomised EORTC trial 22922/10925 investigating internal mammary and medial supraclavicular (IM-MS) lymph node irradiation in stage I-III breast cancer J Clin Oncol 36 504-2589

[17] DiSipio T(2015)Regional nodal irradiation in early-stage breast cancer N Engl J Med 373 307-1459

[18] Rye S(2012)Nomograms for predicting the risk of arm lymphedema after axillary dissection in breast cancer Ann Surg Oncol 19 2580-1972

[19] Newman B(2008)Incidence and risk factors of breast cancer lymphoedema J Clin Nurs 17 1450-3286

[20] Giuliano AE(2009)The risk of developing arm lymphedema among breast cancer survivors: a meta-analysis of treatment factors Ann Surg Oncol 16 1959-571